MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...
This was the stock's second consecutive day of gains.
This was the stock's second consecutive day of losses.
Hosted on MSN11mon
Ocugen (OCGN) Price Target Increased by 58.33% to 6.46The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to 6.46 / share.This is an increase of 58.33% from the prior estimate of 4.08 dated January 16, 2024. The price target ...
Maxim Group analyst Michael Okunewitch has maintained their bullish stance on OCGN stock, giving a Buy rating on January 13.Invest with ...
Ocugen (OCGN) said it has received a positive opinion from EU regulators for Advanced Therapy Medicinal Product ...
Ocugen (OCGN) announced that the European Commission has provided a positive opinion from the EMA’s, or European Medicines Agency’s, Committee ...
As of 12:27:00 PM EST. Market Open. MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company ...
At close: 14 November at 4:00 pm GMT-5 ...
Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback